Authors
Latest:
Dr. Gordon on Toxicities With Immunotherapy in OsteosarcomaNancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses toxicities associated with immunotherapy agents for the treatment of patients with osteosarcoma.
Latest:
Dr. Bartlett on Treatment Regimens for Patients With Hodgkin LymphomaNancy Bartlett, MD, Koman Chair in Medical Oncology, Washington University School of Medicine, Siteman Cancer Center, discusses treatment regimens for patients with Hodgkin lymphoma.
Latest:
Dr. Davidson on the Future of HER2-Targeted Therapies in Breast CancerNancy E. Davidson, MD, discusses the future of HER2-targeted therapies in breast cancer.
Latest:
Hepatic Infusion Can Convert CRC Liver Metastases to Operable StateOverall, compelling response rates and rates of conversion to resection for patients with initially unresectable colorectal liver metastases treated with hepatic arterial infusion suggest consideration of earlier initiation of the technique in chemotherapy-naïve patients as well as its adoption in patients who have failed first-line systemic chemotherapy before proceeding to second- or third-line regimens.
Latest:
The ABCs of IRBs: A Brief OverviewAt some point in their careers, most oncologists will need to submit a research proposal to their hospital's Institutional Review Board. Too many physicians view the IRB process as an additional bureaucratic burden in their already overloaded daily schedules.
Latest:
Dr. Gordon on Immunotherapy Research in OsteosarcomaNancy Gordon, MD, a pediatric oncologist and research assistant at The University of Texas MD Anderson Cancer Center, discusses current immunotherapy research being conducted in the field of osteosarcoma.
Latest:
Dr. Nancy Lewis Discusses the Regorafenib CORRECT TrialNancy L. Lewis, MD, from the Thomas Jefferson University Hospitals, discusses the phase III CORRECT trial that examined the multitargeted tyrosine kinase inhibitor regorafenib.
Latest:
Novel Approach Reduces Treatment Toxicities in Patients With HPV-Related Oropharyngeal CancerThe incidence of mouth and throat cancer is on the rise due to transmission of the human papilloma virus, but physicians at Memorial Sloan Kettering Cancer Center have managed to significantly reduce the intensity of treatment and improve quality of life for these patients.
Latest:
Evolving Treatment Landscape of HER2+ Metastatic Breast CancerClosing out their discussion on novel therapies for HER2+ metastatic breast cancer, experts share excitement for future clinical trials and strategies.
Latest:
Communication Breakdown: Technology in the Exam RoomTechnology and medicine are a wonderful combination, but not if the doctor hides behind it, a real concern in a world of EMRs and handheld medical devices.
Latest:
Dr Lin on the Safety of T-DXd for HER2+ Breast Cancer With/Without Brain MetastasesNancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.
Latest:
Treatment Paradigms Are Shifting for Locally Advanced HPV-Positive Head and Neck CancersA personalized treatment paradigm based on hypoxia imaging is promising and may yield a successful, personalized de-escalation strategy for patients with HPV-associated oropharynx cancer.
Latest:
Dr. Haas on the Role of PSMA in Prostate CancerNaomi B. Haas, MD, discusses the role of prostate-specific membrane antigen in prostate cancer.
Latest:
Dr. Fujioka on Remaining Questions After the PACIFIC Trial in NSCLCNaomi Fujioka, MD, discusses the questions that remain after the PACIFIC trial in stage III non–small cell lung cancer.
Latest:
Dr. Ueno on Liquid BiopsyNaoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses the advantages of liquid biopsy to detect and monitor tumor growth.
Latest:
Dr. Ueno on Patient-Reported Outcomes With Trastuzumab Deruxtecan in HR+/HER2-Low Breast CancerNaoto T. Ueno, MD, PhD, FACP, discusses patient-reported outcomes with fam-trastuzumab deruxtecan-nxki (Enhertu) in hormone receptor (HR)–positive/HER2-low metastatic breast cancer.
Latest:
Dr. Epperla on the Implications of an FDA Approval for Ublituximab/Umbralisib in CLLNarendranath Epperla, MD, MS, discusses the implications of a potential FDA approval for the combination of ublituximab and umbralisib for patients with chronic lymphocytic leukemia.
Latest:
Dr. Duma on the Importance of Mitigating Racial Disparities in Lung Cancer ResearchNarjust Duma, MD, discusses the importance of mitigating racial disparities in lung cancer research.
Latest:
The OCM Is Both Good and QuestionableThe OCM program is a good start on a path that is as rough as it gets in our healthcare system that needs reform, which can't come from legislation such as Obamacare.
Latest:
Dr. Hanna on Challenges With Consolidation Immunotherapy in Lung CancerNasser H. Hanna, MD, discusses challenges in consolation immunotherapy for patients with lung cancer.
Latest:
Dr. Hanna on Approaching Biomarker Testing in Lung CancerNasser H. Hanna, MD, discusses his approach to biomarker testing in lung cancer.
Latest:
Understanding the Smoking GunFor the past 3 decades, Carlos L. Arteaga, MD, has focused his research on drug-resistant breast cancers, seeking to identify the causes of resistance and proposing combination therapies to beat that resistance.
Latest:
Dr Callander on Ongoing and Future Clinical Trials in Multiple Myeloma at Carbone Cancer CenterNatalie S. Callander, MD, discusses several ongoing and planned clinical trials evaluating the use of novel therapeutic regimens in multiple myeloma.
Latest:
Dr Leighl on Amivantamab in Advanced NSCLC With MET Exon 14 Skipping MutationsNatasha B. Leighl, BSc, MMSc, MD, discusses efficacy findings with the EGFR/MET inhibitor amivantamab in patients with advanced non–small cell lung cancer harboring MET exon 14 skipping mutations.
Latest:
Moving to Electronic Prior Authorization Requires Incremental StepsIn a time of tremendous technological advancement, how is it that 90% of communications between providers and payers for prior authorizations are still done by phone or fax, and how do we move to more automated processes?1
Latest:
Dr. Pennell on Understanding the Cost-Effectiveness of Osimertinib in NSCLCNathan A. Pennell, MD, PhD, discusses the importance of understanding the cost-effectiveness of osimertinib in non–small cell lung cancer.
Latest:
Dr. Fowler on Different Responses to Therapy for Follicular LymphomaNathan Fowler, MD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the differences in response to the same therapy for patients with follicular lymphoma.
